All In Biotech

Drug Trial Radar · NCT07940179

Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography

PSMA-PET: Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Nov 4, 2021

Primary completion

Dec 31, 2031

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Jean-Mathieu BeauregardAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to make non-approved PSMA radioligands available at CHU de Québec - Université Laval, while assessing their safety. Our hypothesis is that all the PSMA PET radioligand are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of PSMA-PET will be explored in our clinical setting.

Conditions

  • Prostate Cancer
  • Other Cancers

Interventions

  • PET PSMA tracerDrug

    Administration of a PSMA tracer for PET

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with PSMA PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .Time frame: up to 1 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU de Quebec-Université Laval

    Québec, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.